HaemaLogiX Ltd, a clinical stage biotech, is pleased to announce the appointment of Professor of Medicine and of Laboratory Medicine and Pathology Angela Dispenzieri, M.D. to its Scientific Advisory Board (SAB).
Read article +HaemaLogiX’s South Korean patent 'Kappa Myeloma Antigen Chimeric Receptors and Uses Thereof' was granted in South Korea on 5 January 2024.
Read article +The Board of HaemaLogiX Ltd has appointed non-executive director, Dr, John Cullity, as Chairman of the Company to hold office through the next phase of the Company transformation, which was initiated earlier this year with the announcement of our new CEO.
Read article +HaemaLogiX is pleased to announce that our Chief Manufacturing and Development Officer, Tertia Dex, has been invited to speak at the 2nd Annual Australia Biologics Festival #ABF 2024 held February 20-21 in Melbourne.
Read article +HaemaLogiX Ltd, a clinical stage Australian biotech, is pleased to announce the appointment of Damian Clarke-Bruce as Managing Director and CEO, effective 13 November 2023.
Read article +